HCMR Study

• Research type

  Research Study

• Full title

  HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy

• IRAS ID

  147698

• Contact name

  Stefan Neubauer

• Contact email

  stefan.neubauer@cardiov.ox.ac.uk

• Sponsor organisation

  University of Oxford

• Clinicaltrials.gov Identifier

  NCT01915615

• Research summary

  Hypertrophic cardiomyopathy (HCM) is a condition, mostly inherited, in which the heart muscle becomes thickened. People with this condition usually do not have symptoms. However, in some people with this condition, there is a risk of developing complications such as failure of the heart to pump blood and sudden death. Currently doctors do not know much about why some people develop these complications. The purpose of this study is to find ways of predicting the risk of developing these problems, so that appropriate treatment can be given. This study will carry out a careful and thorough assessment of people with HCM using new sophisticated tests to identify markers that are associated with these complications. This information will help doctors to identify people with HCM who are at higher risks of developing complications in the future as a result of the disease.
  The University of Oxford, UK, in collaboration with the University of Virginia, US are organising this research. The research taking place in Europe is the responsibility of the University of Oxford, while that taking place in North America is the responsibility of the University of Virginia. There will be 40 sites involved in this study as follow:
  1. UK - 11 sites
  2. Germany - 3 sites
  3. Italy - 4 sites
  4. The Netherlands - 2 sites
  5. USA - 17 sites
  6. Canada - 3 sites

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  14/SC/0190

• Date of REC Opinion

  22 May 2014

• REC opinion

  Further Information Favourable Opinion